Incyte Corporation

Quanta Therapeutics, Inc.

Pei Gan

Wenqing Yao

Xiaozhao Wang

Liangxing Wu

Chunhong He

Chao Qi

Peter Niels Carlsen

Le Zhao

Yong Li

Ding-Quan Qian

Wenyu Zhu

Alexander Sokolsky

Fenglei Zhang

Taisheng Huang

Juan Luengo

Hong Lin

Zhiyong Yu

Audrey Hospital

Gia Hoang

Rocco Policarpo

Jin Zeng

Chunyin Marshall Law

Jeffrey Yang

Disclosed are compounds of Formula I, shown below, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Tricyclic compounds as inhibitors of KRAS

Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (I-A), (I-B), (I-C), (I-C*), (I-D), (I-E), (I-F), (I-G), (I-H), (I-I), (I-J), or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any one thereof. The compounds provided herein are useful for modulating KRAS G12D and/or other G12 mutants.

KRAS modulators and uses thereof

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Fused pyrazine derivatives as A2A / A2B inhibitors

Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Vinyl imidazole compounds as inhibitors of KRAS

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors

Growing community of inventors

Claymont, DE, United States of America

Pei Gan